Program
Anti-EpCAM/Anti-CD3 Bispecific Antibody M701
Its studies are mostly in Ascites, led by Wuhan YZY Biopharma.
Furthest: phase 3, since May 18, 20242 company-led studies, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Wuhan YZY Biopharma | 21 open or running | phase 3since May 18, 2024 | Jan 23, 2024 | none ahead |
- Named in sino biopharmaceutical’s own pipeline as
M701
, phase 3, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 23, 2024First study: phase 2 study in Malignant AscitesFirst studyNCT06266091 · 115 enrolled · China
- May 18, 2024Phase 3 study in Malignant AscitesNCT06432296 · 312 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06432296Malignant Ascites · China | 3 | Active, not recruiting | Aug 22, 2025 | 312 |
| NCT06266091Malignant Ascites · China | 2 | Completed | Feb 14, 2024 | 115 |
How it is read
Names in the registry
- “M701”, 2 entries
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.